Overview

* BioCryst Q3 operating profit increased 285% y-o-y, reflecting strong leverage

* ORLADEYO Q3 revenue up 37% y-o-y, driven by strong patient demand

* Company raises FY 2025 ORLADEYO revenue guidance

Outlook

* BioCryst raises FY 2025 ORLADEYO revenue guidance to $590-$600 mln

* Company lowers FY 2025 non-GAAP operating expenses to $430-$440 mln

* Company expects positive cash flows and net income for FY 2025

Result Drivers

* ORLADEYO SALES - Strong patient demand and new prescriber engagement drove 37% y-o-y increase in ORLADEYO revenue

* EUROPEAN BUSINESS SALE - Sale of European ORLADEYO business improved financial leverage and enabled debt retirement

* STRATEGIC ACQUISITION - Planned acquisition of Astria Therapeutics to expand HAE portfolio and drive growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $159.39

Product mln

Sales

Q3 EPS $0.06

Q3 Net $12.89

Income mln

Q3 $129.80

Operatin mln

g

Expenses

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)